Biotech article - March 19, 2025
Scaling the next generation of T-cell therapy
Understanding the science is one thing, but being able to manufacture T-cell therapies at scale is a different matter. TCR-T cell therapies offer a path forward at a fraction of the cost and time of manufacturing a living cell as a product.
Pharma Business - March 4, 2025
AstraZeneca’s Enhertu recommended for approval in the EU by CHMP
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.
Pharma Business - February 25, 2025
Oxcia’s OXC-101 has been granted ODD status
The FDA (the United States Food and Drug Administration ) has granted ODD (orphan drug designation) to OXC-101 as a potential treatment option for patients with AML (acute myeloid leukemia).
Pharma article - February 25, 2025
NMD Pharma announces FDA Orphan Drug designation
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for NMD670, a novel, oral, small molecule inhibitor of the skeletal muscle-specific chloride ion channel ClC-1, for the treatment of Charcot-Marie-Tooth disease (CMT).
Financing - February 17, 2025
AlzeCure receives EU grant for Phase 2 clinical trial
AlzeCure Pharma's project NeuroRestore ACD856 has received EUR 2.5 million from the EU's European Innovation Council.
Pharma Business - February 12, 2025
Lundbeck’s potential treatment for MSA receives Fast Track Designation
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
